ABSTRACT
Impressive advances in treating posttraumatic stress disorder (PTSD) have been made in the past decade with respect to group psychotherapy, individual psychodynamically oriented therapy, and cognitive-behavioral therapy. Notably the Institute of Medicine (1) has recently confirmed the efficacy for exposure-based psychotherapy treatment for PTSD while finding that the current data are inadequate to determine the efficacy of medication treatment for PTSD.(1)
During this same period of time, the neuroscience that underlies the psychotherapy for treating fear-based disorders is rapidly progressing and is being translated to the clinic in the form of pharmacological augmentation of emotional learning.
